Skip to main content
OpenTrials
Completed

NCT Number: NCT01058772

Gestational Diabetes: Induction Versus Expectant Management of Labour

The purpose of this study is to determine whether, in Gestational Diabetes Mellitus (GDM) pregnancies, induction of labour at 38-39 weeks of pregnancy is superior to expectant management in terms of maternal and neonatal outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Helen Schneider's Hospital for Women - Rabin Medical Center, Petah Tikva, Israel

Loading trial locations.

About this study

Gestational Diabetes Mellitus (GDM) is one of the most common complications of pregnancy and its incidence is estimated as around 7%. Babies born from women with GDM are significantly more exposed to perinatal risk. Furthermore in GDM pregnancies an increased C-section rate has been observed, mostly unjustified.

Strong evidence, based on prospective studies and randomized controlled trials, in favour or against the effectiveness and safeness of induction in women with GDM, are missing. The aim of the present study is to identify the best management for these women at term and provide evidence that could change the current clinical practice.

To reach this objective, 1760 eligible women will be recruited at 9 Teaching Hospitals (5 in Italy, 4 all over the world). Sample size has been estimated to demonstrate a difference between the two arms ≥ 6% (31% of C-section in the expectant group and 25% in the induction group; relative difference between the 2 groups equal to 20% in favor of induction; Kjos et al, 1993), considering an α error equal to 5% and 80% power.

Patients will be randomized to induction of labour (N=880) or expectant management (N=880). Data on maternal and neonatal outcomes will be collected at delivery and until maternal and neonatal discharge.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Maternal age > 18;
  • Singleton pregnancy in vertex presentation;
  • Gestational age between 38-39 weeks verified by LMP and first trimester ultrasound when available;
  • Women diagnosed with GDM in the current pregnancy [Diagnosis will be based upon abnormal 50 Gr. GCT (>140) followed by >2 abnormal indices in the OGTT (according to C&C criteria). Women with GCT>200 mg/dl will undergo 100 gr OGTT as well];
  • No other contraindications for vaginal delivery.

Exclusion criteria

  • Pre-gestational diabetes;
  • Prior C-section;
  • Suspected estimated fetal weight> 4000 gr. at enrollment;
  • Any known contraindications for vaginal delivery;
  • Uncertain gestational age;
  • Non-reassuring fetal status necessitating immediate obstetrical intervention (prompt delivery/prompt C-section);
  • Maternal disease complicating pregnancy and necessitating delivery (e.g Severe PET);
  • Bishop score >7 at enrollment;
  • Major fetal malformation.

Treatment and study plan

induction of labour

Other

Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score < 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.

Primary outcomes

  1. C-section rate

    Time frame: 1 minute after delivery

Secondary outcomes

  1. Operative Vaginal Delivery

    Time frame: 1 minute after delivery

  2. Perineal Tears or Episiotomy

    Time frame: 1 minute after delivery

  3. Postpartum haemorrhage

    Time frame: within 24 hours from delivery

  4. Maternal Blood Transfusion

    Time frame: until maternal discharge

  5. Maternal Intensive Care Unit Admission

    Time frame: until maternal discharge

  6. Neonatal Weight

    Time frame: 10 minutes after delivery

  7. Neonatal Apgar score at 1', 5', 10' minutes

    Time frame: 1, 5, 10 minutes after delivery

  8. Shoulder Dystocia

    Time frame: during delivery

  9. Manoeuvres for Shoulder Dystocia

    Time frame: during delivery

  10. Neonatal Intensive Care Unit Admission

    Time frame: until neonatal discharge

  11. Arterial cord Ph inferior to 7.2

    Time frame: within 5 minutes from delivery

  12. Neonatal Hyperbilirubinemia

    Time frame: until neonatal discharge

  13. Clinical and Biochemical Neonatal Hypoglycemia

    Time frame: until neonatal discharge

  14. Neonatal Polycythemia

    Time frame: until neonatal discharge

  15. Neonatal Birth Trauma

    Time frame: 10 minute from delivery or until neonatal discharge

  16. Neonatal Respiratory Distress/Transient Tachypnea

    Time frame: until neonatal discharge

  17. Neonatal Need for Respiratory Support

    Time frame: until neonatal discharge

  18. Maternal death

    Time frame: until neonatal discharge

  19. Perinatal Death

    Time frame: until neonatal discharge

  20. Spontaneous/Instrumental third stage of labour

    Time frame: within 1 hours from delivery

  21. Indication for Cesarean Section

    Time frame: 1 minutes after delivery

Sponsors and collaborators

Lead sponsor

IRCCS Burlo Garofolo

Other

Registry information

Official study title

GINEXMAL RCT: Induction of Labour Versus Expectant Management in Gestational Diabetes Pregnancies

Acronym: GINEXMAL

Important dates

Study start
2010
Primary completion
2014
Study completion
2014
First posted
Jan 29, 2010
Registry last updated
Apr 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.